hydrocortisone sodium succinate 100mg parenteral ordinary dry vials
egyptian international pharmaceutical industries company - hydrocortisone sodium succinate - parenteral ordinary dry vials - 100mg
hydrocortisone sodium succinate for injection bp
lincoln pharmaceuticals ltd c/o medox p.o.box 52771-00200 nairobi - hydrocortisone sodium succinate for injection bp - injection - 100 mg - stomatological preparations: corticosteroids for
hydrocortisone sodium succinate 100mg powder for solution for injection vials
pfizer ltd - hydrocortisone sodium succinate - powder for solution for injection - 100mg
hydrocortisone sodium succinate 100mg/vial parenteral ordinary dry vials
astra pharma (u) limited; astra pharma (u) limited - hydrocortisone sodium succinate - parenteral ordinary dry vials - 100mg/vial
hydrocortisone sodium succinate for injection usp 100mg powder for solution for injection
brawn laboratories limited, india - hydrocortisone sodium succinate - powder for solution for injection - 100mg
hydrocortisone and acetic acid solution
taro pharmaceuticals u.s.a., inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), acetic acid (unii: q40q9n063p) (acetic acid - unii:q40q9n063p) - hydrocortisone 10.4 mg in 1 ml - for the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation. hypersensitivity to hydrocortisone and acetic acid otic solution or any of the ingredients; herpes simplex, vaccinia and varicella. perforated tympanic membrane is considered a contraindication to the use of any medication in the external ear canal.
hydrocortisone- hydrocortisone tablet
major pharmaceuticals - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) - congenital adrenal hyperplasia - nonsuppurative thyroiditis - hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid art
hydrocortisone tablet
stat rx usa llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis or osteoarthritis epicondylitis - collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus
hydrocortisone tablet
physicians total care, inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis or osteoarthritis epicondylitis - collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus
hydrocortisone iodoquinol- hydrocortisone, iodoquinol cream
perrigo new york inc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), iodoquinol (unii: 63w7ie88k8) (iodoquinol - unii:63w7ie88k8) - hydrocortisone 10 mg in 1 g - based on a review of a related drug by the national research council and subsequent fda classification for that drug, the indications are as follows: “possibly” effective: contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. final classification of the less-than-effective indications requires further investigation. hydrocortisone 1%−iodoquinol 1% cream is contraindicated in those patients with a history of hypersensitivity to hydrocortisone, iodoquinol or any other components of the preparation.